Arm CEO says chip shortage delays AI cancer research

Arm Holdings chief executive Rene Haas said that, while current technology cannot yet model the way a specific DNA marker is altered by cancer, future advances in computing are expected to make such analyses possible. Speaking at a technology conference, Haas highlighted the limitations of existing hardware in handling the massive datasets and intricate biochemical interactions required for precise cancer‑genomics modeling, noting that the problem remains beyond the reach of today’s processors.

He added that Arm’s roadmap of increasingly powerful, energy‑efficient chips—combined with progress in artificial‑intelligence accelerators and emerging architectures such as quantum and neuromorphic computing—will eventually provide the computational capacity needed to simulate these complex biological processes. The company is reportedly working with research institutions and biotech firms to align its next‑generation designs with the demands of precision medicine, positioning Arm to support breakthroughs in cancer diagnostics and treatment as the required computing power becomes available.